Investing.com - Financial Markets Worldwide

Starpharma Holdings Ltd (SPL)

Sydney
Symbol
Exchange
Currency
SPL·Sydney·AUD
SPHRY·OTC Markets·USD
Currency in AUD
0.105
0.000(0.00%)
Delayed Data·
SPL Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 12 days
SPL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
0.1050.105
52 wk Range
0.0820.130
Key Statistics
Edit
Bid/Ask
0.10 / 0.105
Prev. Close
0.105
Open
0.105
Day's Range
0.105-0.105
52 wk Range
0.082-0.13
Volume
102.47K
Average Volume (3m)
416.95K
1-Year Change
12.9%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SPL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 10
Quickly burning through cash
Unlock InvestingPro

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Starpharma Holdings Ltd Company Profile

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide. The company’s products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It is also involved in the development of dendrimer enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial. In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; SPL7013 for vaginal gel; and DEP HER2 radiodiagnostic. It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma’s dendrimer technology. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.

Industry
Pharmaceuticals
Sector
Healthcare
Employees
40
Market
Australia

Compare SPL to Peers and Sector

Metrics to compare
SPL
Peers
Sector
Relationship
P/E Ratio
−3.3x−6.0x−0.5x
PEG Ratio
0.09−0.010.00
Price/Book
1.8x1.4x2.6x
Price / LTM Sales
9.9x8.6x3.3x
Upside (Analyst Target)
-221.3%43.4%
Fair Value Upside
Unlock23.6%7.1%Unlock

Earnings

Latest Release
May 28, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
a
a
Unlock
Last 90 days

SPL Income Statement

FAQ

What Stock Exchange Does Starpharma Holdings Trade On?

Starpharma Holdings is listed and trades on the Sydney Stock Exchange stock exchange.

What Is the Stock Symbol for Starpharma Holdings?

The stock symbol for Starpharma Holdings is "SPL."

What Is the Starpharma Holdings Market Cap?

As of today, Starpharma Holdings market cap is 43.91M.

What Is Starpharma Holdings's Earnings Per Share (TTM)?

The Starpharma Holdings EPS (TTM) is -0.03.

When Is the Next Starpharma Holdings Earnings Date?

Starpharma Holdings will release its next earnings report on 19 Aug 2025.

From a Technical Analysis Perspective, Is SPL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Starpharma Holdings Stock Split?

Starpharma Holdings has split 0 times.

How Many Employees Does Starpharma Holdings Have?

Starpharma Holdings has 40 employees.

What is the current trading status of Starpharma Holdings (SPL)?

As of 08 Aug 2025, Starpharma Holdings (SPL) is trading at a price of 0.11, with a previous close of 0.11. The stock has fluctuated within a day range of 0.11 to 0.11, while its 52-week range spans from 0.08 to 0.13.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.